Tango Therapeutics annual meeting elects two Class II directors, ratifies auditor, approves NEO compensation

Tango Therapeutics, Inc.

Peters elected with 98,188,796 for; 17,623,596 withheld; Rothenberg with 92,476,172 for; 23,336,220 withheld.
Ratification of PricewaterhouseCoopers as 2026 auditor: 131,097,992 for, 73,823 against, 26,266 abstain.
Advisory vote on named executive officer compensation: 113,915,877 for, 1,855,838 against, 40,677 abstain.
Director Kanishka Pothula resigned effective May 13, 2026 prior to meeting; not a disagreement with company.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Tango Therapeutics, Inc. shareholders approved Election of Mace Rothenberg, M.D. as Class II director at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Tango Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2026-06-04 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The Company's stockholders approved the non-binding, advisory vote on the compensation of the Company's named executive officers.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Tango Therapeutics, Inc. shareholders approved Election of Malte Peters, M.D. as Class II director at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.

View on SEC.gov

404 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-257760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.